Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AUGUSTO E FOCIL

Allopathic & Osteopathic Physicians Family Medicine

NPI
1407906027
CMS profile
336597
Location
OXNARD, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$845.82

44 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $802.82 42
Education $43.00 2

By paying entity

PY2021 · entire year · sorted by reported total

Page 1 of 1; records 1–44 of 44 matching records. This page contains 44 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AUGUSTO E FOCIL

NPI 1407906027 · CMS profile ID 336597

Allopathic & Osteopathic Physicians / Family Medicine

OXNARD, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–44 of 44 matching records. This page contains 44 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1407906027?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AUGUSTO E FOCIL, NPI 1407906027, CMS profile ID 336597. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–44 of 44 matching records. This page contains 44 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1407906027?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). AUGUSTO E FOCIL, NPI 1407906027, CMS profile ID 336597. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–44 of 44 matching records. This page contains 44 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1407906027?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
AUGUSTO E FOCIL, NPI 1407906027, CMS profile ID 336597, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–44 of 44 matching records. This page contains 44 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1407906027?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

44 matching records · $845.82 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 44 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–44 of 44.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk Inc $19.2512/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811094287 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $26.9511/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763736722 CMS
Biohaven Pharmaceuticals, Inc. $19.5711/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852491541 CMS
AstraZeneca Pharmaceuticals LP $23.4210/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829994197 CMS
AstraZeneca Pharmaceuticals LP $22.3210/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829817323 CMS
Amarin Pharma Inc. $24.7709/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815267491 CMS
Abbott Laboratories $20.5009/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833677799 CMS
MannKind Corporation $19.5308/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821055929 CMS
Novo Nordisk Inc $20.2408/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811094281 CMS
Kowa Pharmaceuticals America, Inc. $15.8107/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805469687 CMS
Esperion Therapeutics, Inc. $20.9607/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838291595 CMS
MannKind Corporation $20.4107/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821055925 CMS
AstraZeneca Pharmaceuticals LP $19.8107/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829768189 CMS
Bioventus LLC $26.3007/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838641155 CMS
Takeda Pharmaceuticals U.S.A., Inc. $25.2806/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819927371 CMS
AstraZeneca Pharmaceuticals LP $19.7006/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829886511 CMS
AstraZeneca Pharmaceuticals LP $22.9006/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830286779 CMS
Novo Nordisk Inc $17.1206/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810872133 CMS
Amarin Pharma Inc. $16.5106/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815268649 CMS
AstraZeneca Pharmaceuticals LP $14.6106/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829560287 CMS
MannKind Corporation $20.5506/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821055921 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $32.5805/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763736724 CMS
Amarin Pharma Inc. $18.7205/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815370307 CMS
Biohaven Pharmaceuticals, Inc. $13.2705/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852491539 CMS
Biohaven Pharmaceuticals, Inc. $24.4805/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852491537 CMS
Merck Sharp & Dohme Corporation $16.0805/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848723577 CMS
AstraZeneca Pharmaceuticals LP $14.4005/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829454549 CMS
Takeda Pharmaceuticals U.S.A., Inc. $18.9205/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819927369 CMS
Biohaven Pharmaceuticals, Inc. $18.9204/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852491535 CMS
MannKind Corporation $16.1204/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821055917 CMS
Novo Nordisk Inc $15.1904/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811392275 CMS
Janssen Pharmaceuticals, Inc $38.0004/28/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788206761 CMS
Janssen Pharmaceuticals, Inc $17.5304/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788206763 CMS
SANOFI-AVENTIS U.S. LLC $15.0404/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843495401 CMS
Novo Nordisk Inc $20.3804/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811554877 CMS
AstraZeneca Pharmaceuticals LP $18.6203/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829880203 CMS
AstraZeneca Pharmaceuticals LP $16.5603/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830057427 CMS
Esperion Therapeutics, Inc. $20.1703/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838291591 CMS
Janssen Pharmaceuticals, Inc $17.7703/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788206765 CMS
SANOFI-AVENTIS U.S. LLC $24.6003/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843495397 CMS
Novo Nordisk Inc $4.5503/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811757107 CMS
AstraZeneca Pharmaceuticals LP $5.0003/05/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829795979 CMS
Novo Nordisk Inc $18.4703/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810736403 CMS
Novo Nordisk Inc $3.9403/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811094273 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,005.14 67
PY2020 $147.59 10
PY2021 $845.82 44
PY2022 $3,925.76 37
PY2023 $246.04 11
PY2024 $245.24 11
PY2025 $50.47 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,708,235.50 545
PY2024 Principal investigator $1,326,172.95 90
PY2023 Principal investigator $2,591,514.80 142
PY2022 Principal investigator $1,448,426.62 96
PY2021 Recipient $668.48 1
PY2021 Principal investigator $1,836,497.66 79
PY2020 Principal investigator $3,489,260.26 87
PY2019 Principal investigator $210,837.51 13

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

142 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $9,930.01 12/31/2023 Non-covered Recipient Entity
FOMAT Medical Research
A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression No dispute reported 06/30/2026 1042522789
Principal investigator 1 ModernaTX, Inc. $10,698.80 12/22/2023 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1041920737
Principal investigator 1 ModernaTX, Inc. $2,025.00 12/22/2023 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1041920795
Principal investigator 1 ModernaTX, Inc. $57,258.60 12/15/2023 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1041920779
Principal investigator 1 Bavarian Nordic A/S $450.00 12/13/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988703449
Principal investigator 1 ModernaTX, Inc. $860.43 12/06/2023 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1041920727
Principal investigator 1 ModernaTX, Inc. $1,831.61 12/04/2023 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1041920745
Principal investigator 1 ModernaTX, Inc. $5,826.71 12/04/2023 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1041920753
Principal investigator 1 ModernaTX, Inc. $30,591.00 12/04/2023 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1041920789
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997159333
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997159339
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997159347
Principal investigator 1 ModernaTX, Inc. $110,685.40 11/22/2023 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1041920605
Principal investigator 1 ModernaTX, Inc. $550.00 11/22/2023 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1041920671
Principal investigator 1 PFIZER INC. $30,375.00 11/22/2023 Non-covered Recipient Entity
FOMAT Medical Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045875325
Principal investigator 1 Bavarian Nordic A/S $450.00 11/15/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988703461
Principal investigator 1 ModernaTX, Inc. $1,167.73 11/10/2023 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1041919951
Principal investigator 1 PFIZER INC. $7,000.00 11/08/2023 Non-covered Recipient Entity
FOMAT Medical Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045875311
Principal investigator 1 ModernaTX, Inc. $550.00 11/03/2023 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1041920679
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997159313
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997159321
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997159327
Principal investigator 1 ModernaTX, Inc. $330.00 10/27/2023 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1041920463
Principal investigator 1 ModernaTX, Inc. $550.00 10/27/2023 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1041920471
Principal investigator 1 Bavarian Nordic A/S $1,805.49 10/25/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988703437
Principal investigator 1 Bavarian Nordic A/S $364.50 10/25/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988703443
Principal investigator 1 Bavarian Nordic A/S $175.50 10/20/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988703467
Principal investigator 1 ModernaTX, Inc. $2,736.90 10/20/2023 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041919861
Principal investigator 1 ModernaTX, Inc. $81,536.15 10/20/2023 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1041920447
Principal investigator 1 ModernaTX, Inc. $550.00 10/18/2023 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1041919919
Principal investigator 1 Bavarian Nordic A/S $71,381.25 10/06/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988703455
Principal investigator 1 ModernaTX, Inc. $29,061.45 10/06/2023 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1041919911
Principal investigator 1 ModernaTX, Inc. $1,591.94 10/04/2023 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041919869
Principal investigator 1 ModernaTX, Inc. $161,934.40 10/02/2023 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1041919903
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997159153
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997159159
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997159165
Principal investigator 1 Bavarian Nordic A/S $729.00 09/27/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988703413
Principal investigator 1 Bavarian Nordic A/S $3,610.98 09/22/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988703407
Principal investigator 1 ModernaTX, Inc. $142.00 09/22/2023 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041919813
Principal investigator 1 ModernaTX, Inc. $550.00 09/15/2023 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1041919845
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997159133
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997159139
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997159145
Principal investigator 1 Bavarian Nordic A/S $15,346.66 08/30/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988703401
Principal investigator 1 PFIZER INC. $14,486.88 08/23/2023 Non-covered Recipient Entity
FOMAT Medical Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045913983
Principal investigator 1 Bavarian Nordic A/S $13,486.50 08/16/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988703395
Principal investigator 1 ModernaTX, Inc. $79,798.70 08/16/2023 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1041919779
Principal investigator 1 ModernaTX, Inc. $1,864.38 08/11/2023 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041919537
Principal investigator 1 ModernaTX, Inc. $550.00 08/09/2023 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1041919787
Principal investigator 1 ModernaTX, Inc. $6,002.36 08/04/2023 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041919545
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997159115
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997159121
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997159127
Principal investigator 1 ModernaTX, Inc. $1,726.44 07/28/2023 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041919529
Principal investigator 1 Bavarian Nordic A/S $450.00 07/26/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988703419
Principal investigator 1 ModernaTX, Inc. $92,325.20 07/21/2023 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1041919747
Principal investigator 1 Bavarian Nordic A/S $23,506.60 07/19/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988703389
Principal investigator 1 Bavarian Nordic A/S $450.00 07/14/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988703431
Principal investigator 1 ModernaTX, Inc. $51,363.50 07/14/2023 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1041919755
Principal investigator 1 ModernaTX, Inc. $550.00 07/14/2023 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1041919765
Principal investigator 1 Bavarian Nordic A/S $900.00 07/07/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988703425
Principal investigator 1 ModernaTX, Inc. $3,128.81 07/07/2023 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041919519
Principal investigator 1 ModernaTX, Inc. $550.00 07/07/2023 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1041919773
Principal investigator 1 PFIZER INC. $1,091.88 07/06/2023 Non-covered Recipient Entity
FOMAT Medical Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045919457
Principal investigator 1 GlaxoSmithKline, LLC. $542.96 07/03/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A PHASE III, RANDOMIZED, OPEN-LABEL, CONTROLLED, MULTI-CENTER STUDY TO No dispute reported 06/30/2026 1006239813
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997159097
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997159103
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997159109
Principal investigator 1 ModernaTX, Inc. $976.36 06/28/2023 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041919503
Principal investigator 1 PFIZER INC. $20,911.96 06/27/2023 Non-covered Recipient Entity
FOMAT Medical Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045900977
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,750.00 06/26/2023 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997159041
Principal investigator 1 ModernaTX, Inc. $2,204.55 06/14/2023 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041919465
Principal investigator 1 ModernaTX, Inc. $2,204.55 06/14/2023 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041919471
Principal investigator 1 ModernaTX, Inc. $72,097.41 06/14/2023 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041919481
Principal investigator 1 ModernaTX, Inc. $15,431.85 06/14/2023 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041919489
Principal investigator 1 ModernaTX, Inc. $2,000.31 06/14/2023 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041919497
Principal investigator 1 ModernaTX, Inc. $2,007.90 06/14/2023 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041919512
Principal investigator 1 ModernaTX, Inc. $34,382.85 06/14/2023 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1041919739
Principal investigator 1 PFIZER INC. $26,291.44 06/08/2023 Non-covered Recipient Entity
FOMAT Medical Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045915201
Principal investigator 1 ModernaTX, Inc. $350.00 06/07/2023 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
Observational secondary-use comparative effectiveness cohort study with tokenized clinical trial and real-world data. No dispute reported 06/30/2026 1041919975
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997159079
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997159085
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997159091
Principal investigator 1 ModernaTX, Inc. $78,303.95 05/26/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1041923511
Principal investigator 1 PFIZER INC. $8,302.56 05/26/2023 Non-covered Recipient Entity
FOMAT Medical Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045912401
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,418.75 05/23/2023 Non-covered Recipient Entity
Medical University Of Sc, Hollings Cancer Center
A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF BMS-986036 (PEG-FGF21) IN ADULTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) AND STAGE 3 LIVER FIBROSIS No dispute reported 06/30/2026 1027450801
Principal investigator 1 ModernaTX, Inc. $54,578.65 05/19/2023 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
Observational secondary-use comparative effectiveness cohort study with tokenized clinical trial and real-world data. No dispute reported 06/30/2026 1041919957
Principal investigator 1 ModernaTX, Inc. $350.00 05/19/2023 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
Observational secondary-use comparative effectiveness cohort study with tokenized clinical trial and real-world data. No dispute reported 06/30/2026 1041919965
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,000.00 05/12/2023 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997159029
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,500.00 05/12/2023 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997159035
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,000.00 05/12/2023 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997159047
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,500.00 05/12/2023 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997159055
Principal investigator 1 ModernaTX, Inc. $4,661.30 05/03/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041923405
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997159061
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997159067
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997159073
Principal investigator 1 Novo Nordisk AS $830.00 04/26/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
NN9535-4416 No dispute reported 06/30/2026 1007237665
Principal investigator 1 ModernaTX, Inc. $9,034.53 04/19/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041923389
Principal investigator 1 ModernaTX, Inc. $4,128.27 04/19/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041923397
Principal investigator 1 ModernaTX, Inc. $117,176.90 04/19/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1041923495
Principal investigator 1 ModernaTX, Inc. $500.00 04/19/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1041923503
Principal investigator 1 Eli Lilly and Company $109,365.00 04/18/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1038091029
Principal investigator 1 ModernaTX, Inc. $1,745.78 04/14/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041923381
Principal investigator 1 PFIZER INC. $800.00 04/12/2023 Non-covered Recipient Entity
FOMAT Medical Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045904321
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997158997
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997159003
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997159009
Principal investigator 1 Bavarian Nordic A/S $110,766.15 03/29/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988703383
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17,366.00 03/28/2023 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997159021
Principal investigator 1 ModernaTX, Inc. $146,117.95 03/24/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1041923487
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $294,588.13 03/23/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INCORPORATED
A MASTER PROTOCOL ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF AMBULATORY PATIENTS WITH COVID-19 No dispute reported 06/30/2026 977100751
Principal investigator 1 ModernaTX, Inc. $500.00 03/22/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1041923479
Principal investigator 1 ModernaTX, Inc. $2,141.13 03/17/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041923373
Principal investigator 1 GlaxoSmithKline, LLC. $29,744.35 03/15/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A PHASE III, RANDOMIZED, OPEN-LABEL, CONTROLLED, MULTI-CENTER STUDY TO No dispute reported 06/30/2026 1006239827
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,533.23 03/15/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INCORPORATED
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES IN PREVENTING SARS-COV-2 INFECTION IN HOUSEHOLD CONTACTS OF INDIVIDUALS INFECTED WITH SARS-COV-2 No dispute reported 06/30/2026 977098783
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997158979
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997158985
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997158991
Principal investigator 1 Bavarian Nordic A/S $3,000.00 02/24/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988703377
Principal investigator 1 ModernaTX, Inc. $101,554.05 02/22/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1041923471
Principal investigator 1 PFIZER INC. $32,162.61 02/22/2023 Non-covered Recipient Entity
FOMAT Medical Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045904785
Principal investigator 1 ModernaTX, Inc. $2,150.37 02/17/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041923365
Principal investigator 1 Bavarian Nordic A/S $120,407.85 02/15/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988703371
Principal investigator 1 ModernaTX, Inc. $10,000.00 02/15/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041923357
Principal investigator 1 ModernaTX, Inc. $500.00 02/10/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1041923463
Principal investigator 1 GlaxoSmithKline, LLC. $20,487.17 02/08/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A PHASE III, RANDOMIZED, OPEN-LABEL, CONTROLLED, MULTI-CENTER STUDY TO No dispute reported 06/30/2026 1006239821
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,500.00 02/03/2023 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997159015
Principal investigator 1 GlaxoSmithKline, LLC. $906.88 02/03/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A PHASE III, RANDOMIZED, OPEN-LABEL, CONTROLLED, MULTI-CENTER STUDY TO No dispute reported 06/30/2026 1006239833
Principal investigator 1 ModernaTX, Inc. $70,291.80 02/01/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1041923453
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997158961
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997158967
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997158973
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,830.00 01/26/2023 Non-covered Recipient Entity
Fomat Medical Research Incorporated
A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF BMS-986036 (PEG-FGF21) IN ADULTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) AND STAGE 3 LIVER FIBROSIS No dispute reported 06/30/2026 1027448729
Principal investigator 1 ModernaTX, Inc. $500.00 01/20/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1041923445
Principal investigator 1 ModernaTX, Inc. $3,990.00 01/18/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1041923421
Principal investigator 1 ModernaTX, Inc. $326.89 01/18/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1041923429
Principal investigator 1 ModernaTX, Inc. $3,250.00 01/18/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1041923437
Principal investigator 1 ModernaTX, Inc. $1,300.00 01/18/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1041923519
Principal investigator 1 ModernaTX, Inc. $79,548.10 01/13/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1041923413
Principal investigator 1 Eli Lilly and Company $1,630.79 01/10/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1038102383
Principal investigator 1 ModernaTX, Inc. $2,655.76 01/04/2023 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041923349